Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 993

1.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.

Clin Cancer Res. 2003 Sep 15;9(11):4108-15.

2.

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

Kelly K, Pan Z, Murphy J, Huffman DH, Bunn PA Jr.

Clin Cancer Res. 1997 Jul;3(7):1117-23.

3.

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.

Clin Cancer Res. 2001 Dec;7(12):3912-9.

4.

Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-81-S12-88.

PMID:
9331128
5.

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.

Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508.

6.

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.

Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1996 Dec;23(6 Suppl 16):35-41.

PMID:
9007119
7.

Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.

PMID:
7544025
8.

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-73-S12-80.

PMID:
9331127
9.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.

Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9. Epub 2006 Oct 10.

PMID:
17031646
10.

One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial.

Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M, Greco FA.

Eur J Cancer. 1998 Apr;34(5):654-8.

PMID:
9713269
11.

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.

Scagliotti GV, Crinó L, Pozzi E, Corgna E, Selvaggi G, Novello S, Salsano G, Gentile A, Palladino M, Marracolo F, Tonato M.

Lung Cancer. 1999 Jul;25(1):39-46.

PMID:
10466861
12.

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.

Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, Maneechavakajorn J, Sirachainant E, Arpornvivat W, Jaisathaporn K, Ratanatharathorn V.

Lung Cancer. 1999 Dec;26(3):175-85.

PMID:
10598928
13.

Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.

Novello S, Galli L, Antonuzzo A, Crinó L, Pozzi E, Selvaggi G, Ricci S, Marrocolo F, Darwish S, Sorbolini S, Tonato M, Scagliotti GV.

Lung Cancer. 2001 Nov;34(2):261-9.

PMID:
11679185
14.
15.
16.

Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.

Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M.

Jpn J Clin Oncol. 2005 Apr;35(4):188-94. Review.

PMID:
15845567
17.

A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.

Ichiki M, Kawasaki M, Takayama K, Ninomiya K, Kuba M, Iwami F, Miyazaki N, Oishi K, Takeo S, Aizawa H, Nakanishi Y.

Cancer Chemother Pharmacol. 2006 Sep;58(3):368-73. Epub 2006 Jan 4.

PMID:
16395589
18.
19.

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Goffin JR, Anderson IC, Supko JG, Eder JP Jr, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.

Clin Cancer Res. 2005 May 1;11(9):3417-24.

20.

High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.

Rosenman JG, Halle JS, Socinski MA, Deschesne K, Moore DT, Johnson H, Fraser R, Morris DE.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):348-56.

PMID:
12243807

Supplemental Content

Support Center